This triplet regimen leverages the complementary mechanisms of action of each agent: bendamustine exerts direct cytotoxic effects on malignant cells; rituximab mediates antibody‐dependent cellular cytotoxicity via CD20 targeting; and acalabrutinib disrupts BTK‐driven survival and proliferation signaling in MCL cells. Here, BTK is linked to mantle cell lymphoma.